Melanoma Clinical Trials in Nashville

Showing 241-260 of 286 trials

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994

This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + Sorafenib or DTIC + Placebo.

CancerMelanoma

Bayer101 participantsStarted Apr 2005

Tucson, Arizona, United States • Aurora, Colorado, United States • Lakeland, Florida, United States +11 more locations

WITHDRAWN< 1 mile

Autonomic Phenotype Before and After Akt Inhibition

NCT01593579

Some Akt inhibitors have produced functional cardiovascular effects such as marked hypotension that may limit their clinical benefit. There are no current data on whether this autonomic failure presents in humans at clinically used doses. We will test the hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood pressure.

Diagnosis of Melanoma

Vanderbilt UniversityStarted May 2012

Nashville, Tennessee, United States

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Autonomic Phenotype Before and After Akt Inhibition

Melanoma Trials in Other Cities

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Phase II, 2nd Line Melanoma - RAND Monotherapy

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

CCI-779 in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

SciBase International Melanoma Pivotal Study

Other Conditions in Nashville